HBOX Therapies has developed a technology that facilitates lung-protective treatment of respiratory patients, the patented platform technology HBOX (Hyperbaric Blood Oxygenation). The management team of HBOX Therapies consists of the founders and shareholders Dr. Peter Schlanstein, Dr. Matthias Menne and Niklas Steuer. Before founding the company, they worked together for many years at the Institute for Applied Medical Technology (AME) at RWTH Aachen University and are highly specialized in their fields.
inContAlert was founded in September 2022 within the ecosystem of the University of Bayreuth. The MedTech startup's sensor system empowers patients with neurogenic bladder dysfunction to manage their bladder on a needs-based basis.
Sedivention is developing a medical device for a new therapy of obesity. The Blizzard cryocatheter freezes the nerve branches, that transmit an increased, inadequate feeling of hunger to the brain in obese people, from inside the stomach. The hunger feeling is reduced in a one-off, minimally invasive intervention, similar to a gastroscopy. Our aim is to help obese people lose weight and thus reduce their risk of secondary diseases such as diabetes, hypertension and cancer. And we do this without surgery, without implants, without lifelong medication.
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying.
The present prototype has successfully completed initial animal studies (ZIM-funded). Following successful CE certification, commercialization as a class IIb product is expected to start in 2027.
The Trans-Duodenal Barrier is a globally unique product for the pronounced growth market of obesity, DMT2 and NASH (approx. 800 million patients worldwide) and already has a sales potential in the billions at 0.1% penetration.
The uniqueness of the Trans-Duodenal Barrier is based in particular on the patented method of fixation and therefore also allows much broader use than previous methods for combining restrictive and malabsorptive principles of action.
Die Einzigartigkeit der Trans-Duodenal Barrier fußt insbesondere auf der patentierten Art der Fixierung und erlaubt daher auch wesentlich breitere Verwendung als bisherige Verfahren zur Kombination restriktiver und malabsorptiver Wirkprinzipien
